News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals Inc Cl A
(NQ:
RXRX
)
6.320
-0.360 (-5.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Recursion Pharmaceuticals Inc Cl A
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Today 15:23 EDT
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.
Via
Benzinga
Topics
ETFs
Stocks
Exposures
US Equities
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
October 26, 2024
This company stands to benefit from a shifting pharmaceutical industry landscape.
Via
The Motley Fool
Prediction: These 2 Stocks Could Soar in 2025
October 17, 2024
The key word here is "could."
Via
The Motley Fool
Cathie Wood Is Betting on This AI Stock: Is It a Buy?
October 15, 2024
Wood has a stake in this stock, but it's hardly an "all-in" bet.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?
October 15, 2024
This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is Recursion Pharmaceuticals Stock a Buy?
September 20, 2024
It largely depends on your investing style.
Via
The Motley Fool
Looking Into Recursion Pharmaceuticals's Recent Short Interest
September 16, 2024
Via
Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
October 08, 2024
The popular growth investor keeps adding to some of her favorite falling stocks.
Via
The Motley Fool
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
October 07, 2024
These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
September 29, 2024
The Ark Invest portfolio is known for taking aggressive bets.
Via
The Motley Fool
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
September 15, 2024
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual...
Via
Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
September 10, 2024
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual...
Via
Talk Markets
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
September 04, 2024
Via
Benzinga
How Is The Market Feeling About Recursion Pharmaceuticals?
August 23, 2024
Via
Benzinga
These AI-Related Stocks Were Down +10% Week Ending September 6
September 07, 2024
AI-related tech stocks plummeted this week with the August ISM manufacturing index report that figures that came in below consensus expectations raising fears about the strength of the economy and that...
Via
Talk Markets
Topics
Economy
Exposures
Economy
Interest Rates
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
September 05, 2024
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug...
Via
Talk Markets
Topics
Economy
Exposures
Economy
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
September 03, 2024
Via
Benzinga
Exposures
Fossil Fuels
Nasdaq Dips Over 2%; US Construction Spending Falls In July
September 03, 2024
Via
Benzinga
Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On?
September 03, 2024
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation...
Via
Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 03, 2024
Via
Benzinga
Is Recursion Pharmaceuticals a Warren Buffett Stock?
August 30, 2024
Don't expect Buffett to invest in this stock tomorrow, but it has the potential to eventually be a stock he would consider.
Via
The Motley Fool
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
August 27, 2024
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030.
Via
Talk Markets
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
August 18, 2024
Merging with a former rival will bolster its capabilities.
Via
The Motley Fool
Is Recursion Pharmaceuticals Stock a Buy?
August 17, 2024
We'll know a little more about the biotech's prospects in a year and a half.
Via
The Motley Fool
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
August 14, 2024
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion...
Via
Talk Markets
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
August 13, 2024
Efficiency in core processes is set to increase substantially due to AI.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
August 12, 2024
There isn't much to suggest these businesses are actually vulnerable.
Via
The Motley Fool
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
August 11, 2024
The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
August 08, 2024
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
RXRX Stock Earnings: Recursion Pharmaceuticals Meets EPS, Beats Revenue for Q2 2024
August 08, 2024
RXRX stock results show that Recursion Pharmaceuticals met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.